Etybenzatropine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Etybenzatropine
Accession Number
DB13468
Description
Not Available
Type
Small Molecule
Groups
Experimental
Structure
Thumb
Weight
Average: 321.464
Monoisotopic: 321.209264493
Chemical Formula
C22H27NO
Synonyms
  • Ethybenztropine
External IDs
  • UK-738

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcetazolamideAcetazolamide may increase the central nervous system depressant (CNS depressant) activities of Etybenzatropine.
AcetophenazineAcetophenazine may increase the central nervous system depressant (CNS depressant) activities of Etybenzatropine.
AclidiniumThe risk or severity of adverse effects can be increased when Etybenzatropine is combined with Aclidinium.
AdenosineThe risk or severity of Tachycardia can be increased when Adenosine is combined with Etybenzatropine.
AgomelatineAgomelatine may increase the central nervous system depressant (CNS depressant) activities of Etybenzatropine.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Etybenzatropine.
AlimemazineAlimemazine may increase the central nervous system depressant (CNS depressant) activities of Etybenzatropine.
AlloinThe therapeutic efficacy of Alloin can be decreased when used in combination with Etybenzatropine.
AlmotriptanAlmotriptan may increase the central nervous system depressant (CNS depressant) activities of Etybenzatropine.
AlosetronAlosetron may increase the central nervous system depressant (CNS depressant) activities of Etybenzatropine.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Categories

ATC Codes
N04AC30 — Etybenzatropine
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Diphenylmethanes
Direct Parent
Diphenylmethanes
Alternative Parents
Tropane alkaloids / Benzylethers / Piperidines / N-alkylpyrrolidines / Trialkylamines / Dialkyl ethers / Azacyclic compounds / Hydrocarbon derivatives
Substituents
Amine / Aromatic heteropolycyclic compound / Azacycle / Benzylether / Dialkyl ether / Diphenylmethane / Ether / Hydrocarbon derivative / N-alkylpyrrolidine / Organic nitrogen compound
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Chemical Identifiers

UNII
G1X2X9N95N
CAS number
524-83-4
InChI Key
PHTMLLGDZBZXMW-AERCQKQUSA-N
InChI
InChI=1S/C22H27NO/c1-2-23-19-13-14-20(23)16-21(15-19)24-22(17-9-5-3-6-10-17)18-11-7-4-8-12-18/h3-12,19-22H,2,13-16H2,1H3/t19-,20+,21+
IUPAC Name
(1R,3S,5S)-3-(diphenylmethoxy)-8-ethyl-8-azabicyclo[3.2.1]octane
SMILES
CCN1[[email protected]]2CC[[email protected]@H]1C[[email protected]@H](C2)OC(C1=CC=CC=C1)C1=CC=CC=C1

References

General References
Not Available
ChemSpider
16736129
RxNav
1358000
ChEBI
135972
ChEMBL
CHEMBL2104273
ZINC
ZINC000100203405
Wikipedia
Etybenzatropine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00115 mg/mLALOGPS
logP5.09ALOGPS
logP4.54ChemAxon
logS-5.4ALOGPS
pKa (Strongest Basic)9.82ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area12.47 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity98.99 m3·mol-1ChemAxon
Polarizability37.59 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on June 23, 2017 14:42 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates